Literature DB >> 497521

Influence of fasting and cimetidine on the relationship between ulcerogenic and anti-inflammatory properties of indomethacin.

P Del Soldato, A Meli, G Volterra.   

Abstract

1 Further studies have been carried out on the relationship between ulcerogenic and anti-inflammatory properties of indomethacin in the rat. 2 Fasting, which increases gastric and reduces intestinal lesions, enhances the anti-oedema properties of indomethacin. 3 The presence of intestinal lesions, greatly increases the anti-oedema properties of indomethacin through a mechanism(s) unrelated to the specific pharmacological properties of this drug. 4 Studies with cimetidine, have shown that the enhancement of anti-oedema effects produced by fasting are due to specific pharmacological properties of indomethacin rather than to non specific effects related to the presence of gastric ulcers. 5 The greater anti-inflammatory effects of indomethacin in fasted as compared to fed animals must be attributed to the greater amount of indomethacin available for tissue distribution rather than other mechanisms associated with free fatty acid mobilization. 6 In view of ineffectiveness in preventing intestinal lesions, the use of cimetidine for prevention or reduction of indomethacin-induced gastrointestinal disturbances in humans is contraindicated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 497521      PMCID: PMC2043600     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs.

Authors:  C A WINTER; E A RISLEY; G W NUSS
Journal:  Proc Soc Exp Biol Med       Date:  1962-12

2.  The colorimetric micro-determination of long-chain fatty acids.

Authors:  W G Duncombe
Journal:  Biochem J       Date:  1963-07       Impact factor: 3.857

3.  Kinetics of indomethacin absorption, elimination, and enterohepatic circulation in man.

Authors:  K C Kwan; G O Breault; E R Umbenhauer; F G McMahon; D E Duggan
Journal:  J Pharmacokinet Biopharm       Date:  1976-06

4.  Factors influencing the development of indomethacin-induced intestinal ulcers in the rat.

Authors:  G Volterra; N Pisanti; A Meli
Journal:  Proc Soc Exp Biol Med       Date:  1974-05

5.  An extended study of indomethacin. I. Clinical pharmacology.

Authors:  N O Rothermich
Journal:  JAMA       Date:  1966-02-14       Impact factor: 56.272

6.  Factors influencing indomethacin toxicity in the rat.

Authors:  P Del Soldato; A Meli
Journal:  Farmaco Sci       Date:  1977-12

7.  Effects of cimetidine, a histamine H2-receptor antagonist, on various experimental gastric and duodenal ulcers.

Authors:  S Okabe; K Takeuchi; T Urushidani; K Takagi
Journal:  Am J Dig Dis       Date:  1977-08

8.  Indomethacin: relationship between ulcerogenic and anti-inflammatory properties. I. Effects of an intestinal lesion-preventing fat-free diet on anti-edema and anti-granuloma properties of indomethacin in the rat.

Authors:  G Volterra; P Del Soldato; A Meli
Journal:  Proc Soc Exp Biol Med       Date:  1978-04

9.  Further investigations of indomethacin and intestinal ulcers in the rat.

Authors:  P Del Soldato; A Meli
Journal:  Toxicology       Date:  1978-02       Impact factor: 4.221

10.  Comparative bioavailability: influence of various diets on the bioavailability of indomethacin.

Authors:  W W Wallusch; H Nowak; G Leopold; K J Netter
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-01
View more
  2 in total

1.  Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(d,l-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in rats.

Authors:  N Ammoury; H Fessi; J P Devissaguet; M Dubrasquet; S Benita
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

2.  Effect of the COX-2 selective inhibitor l-745,337 on inflammation and organ prostaglandin E2 (PGE2) levels in adjuvant arthritic rats.

Authors:  N Turull; J Queralt
Journal:  Inflammation       Date:  2000-12       Impact factor: 4.092

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.